Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca - LARVOL DELTA

First-Line Trastuzumab Deruxtecan (T-DXd) in Patients With Metastatic HER2 -Mutant NSCLC: DESTINY-Lung04 Primary Results (IASLC-WCLC 2026) - P3 | "Patients were randomized 1:1 to T-DXd 5.4 mg/kg IV Q3W or pembro 200 mg IV Q3W plus platinum chemo (cisplatin 75 mg/m 2 or carboplatin AUC 5 IV Q3W) and pemetrexed 500 mg/m 2 IV Q3W. Safety was generally consistent with the known profile of T-DXd. These results support T-DXd as a new first-line option for advanced/metastatic HER2 -mutant NSCLC."

Clinical • IO biomarker • Late-breaking abstract • Metastases • Inflammation • Interstitial Lung Disease • Lung Cancer • Non Small Cell Lung Cancer • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • HER-2

Final results of TALENT: A neoadjuvant trial of T-DXd with or without anastrozole, or in sequence with chemotherapy for HER2-low, HR+ early-stage breast cancer (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

First-line (1L) trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutant (HER2m) NSCLC: patient-reported outcomes (PROs) from DESTINY-Lung04 (DL-04) (ESMO 2026) - No abstract available

Clinical • Late-breaking abstract • Patient reported outcomes • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2

Interstitial Lung Disease and Cardiotoxicity Associated with Trastuzumab Deruxtecan, Sacituzumab Govitecan, and Trastuzumab Emtansine: A Narrative Review. (PubMed, Medicina (Kaunas)) - "Monitoring intensity, diagnostic thresholds, and management pathways must be tailored to the individual drug, regimen, indication, dose, patient comorbidity, and prior therapy. Close collaboration among oncology, radiology, pulmonology, and cardio-oncology is essential to preserve both treatment efficacy and patient safety."

Adverse events • Journal • Review • Breast Cancer • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Inflammation • Interstitial Lung Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor

Current and Emerging Targeted Therapy in Advanced Gastroesophageal Adenocarcinoma. (PubMed, Pharmaceuticals (Basel)) - " HER2-directed therapy has progressed from trastuzumab through dual blockade, immunotherapy combinations, next-generation ADCs (notably trastuzumab deruxtecan) and bispecific antibodies such as zanidatamab, which has now overtaken trastuzumab in the first-line setting. CLDN18.2-targeted zolbetuximab has demonstrated survival benefit in biomarker-selected patients, with newer ADCs, BiTEs and the first approved solid-tumour CAR-T therapy (satricabtagene autoleucel) extending this target further. VEGFR2 inhibition with ramucirumab remains a cornerstone in later lines, while novel VEGF/PD-1(L1) bispecifics are under investigation. FGFR2b-targeted bemarituzumab showed early promise that weakened on phase 3 confirmation, and MET/EGFR-directed agents, including savolitinib and amivantamab, require stringent biomarker selection to demonstrate benefit amid tumour heterogeneity. Novel targeted agents, particularly to HER2 and CLDN18.2, have demonstrated survival benefit despite..."

IO biomarker • Journal • Review • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • CLDN18

A Multicenter Prospective Observational Study Evaluating Effectiveness and Safety of Trastuzumab Deruxtecan in HER2-Positive Gastric Cancer Patients without HER2 Status Immediately Prior to Second-Line Treatment (clinicaltrials.gov) - P=N/A | N=100 | Not yet recruiting | Sponsor: NAGOYA UNIVERSITY HOSPITAL

New trial • Esophageal Cancer • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

A multicenter retrospective observational study of real-world T-DXd treatment for stage4 HER2-mutated non-small cell lung cancer patients in Japan (REAL-HER2 Study) (WJOG21224L) (clinicaltrials.gov) - P=N/A | N=70 | Active, not recruiting | Sponsor: West Japan Oncology Group | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2

Individualizing Trastuzumab Deruxtecan (T-DXd) Therapy: Molecular Tumor Board-Guided Dose Modifications and Combination Strategies in Real-World Practice (ESMO 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Oncology

AstraZeneca Pharmaceuticals LP, and Daiichi Sankyo, Inc. - Cases and Conversations – Evolving Radiation Strategies in HER2-Positive Breast Cancer: Early-Stage Through Metastatic Disease (ASTRO 2026) - "learning objectives Evaluate the safety profile of concurrent and sequential radiation therapy with T-DXd, including strategies to distinguish drug-related ILD from radiation pneumonitis...Assess the implications of recent and emerging clinical trial data for the role of radiation therapy in early-stage and metastatic HER2-positive breast cancer. Apply a multidisciplinary framework to integrate systemic and local therapy for HER2-positive breast cancer with brain metastases."

Clinical • Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Radiation Recall with ADCs - Radiation Recall Phenomenon in the Era of T-DXd, Sacituzumab Govitecan, (ESMO 2026) - No abstract available

ADC • Oncology

Real world safety and efficacy of Trastuzumab Deruxtecan (T-DXd) in HER2 expressing solid tumors: a retrospective cohort study from an Asian tertiary centre (ESMO 2026) - No abstract available

Real-world • Real-world evidence • Retrospective data • Oncology • Solid Tumor • HER-2

Radiation Modulates HER2 Expression and Trastuzumab Deruxtecan Response in HER2-Low Metastatic Breast Cancer (ASTRO 2026) - "Low-dose RT reprograms HER2-low breast cancer brain metastases by increasing tumor surface HER2 expression and enhancing ADC internalization. These findings support a radiation-priming strategy to optimize T-DXd efficacy in CNS disease. Prospective studies are warranted to define optimal radiation dosing and sequencing to improve intracranial control in HER2-low breast cancer."

Metastases • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Impact of prior immune checkpoint inhibitor (ICI) treatments on the clinical outcomes of trastuzumab deruxtecan (T-DXd) vs ramucirumab (RAM) + paclitaxel (PTX) in human epidermal growth factor receptor 2–positive (HER2+) advanced gastric cancer (GC)/ gastroesophageal junction adenocarcinoma (GEJA): exploratory analysis from DESTINY-Gastric04 (DG-04) (ESMO 2026) - No abstract available

Checkpoint inhibition • Clinical • Clinical data • Metastases • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor • HER-2

Real-World (RW) Analysis of Trastuzumab Deruxtecan (T-DXd) or Docetaxel as Second-Line or Later (2L+) Treatment in Human Epidermal Growth Factor Receptor 2 Mutant (HER2m) Advanced Non–Small Cell Lung Cancer (aNSCLC) (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2

THUMB: T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis (clinicaltrials.gov) - P2 | N=140 | Recruiting | Sponsor: Fudan University | Not yet recruiting ➔ Recruiting

Enrollment open • Brain Cancer • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

Real-world Clinical Outcomes After T-DXd and Subsequent HER2 Therapy (ESMO 2026) - No abstract available

Clinical • Clinical data • Real-world • Real-world evidence • Oncology

Enhanced protein lactylation accompanies acquired resistance to trastuzumab deruxtecan in HER2-positive breast cancer (ESMO 2026) - No abstract available

Preclinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Objective response rate and depth of response with trastuzumab deruxtecan across the human epidermal growth factor receptor 2 spectrum and treatment settings: a systematic review and meta-regression of the DESTINY-Breast clinical trials (ESMO 2026) - No abstract available

Clinical • Review • Oncology • HER-2

Efficacy and Safety of Trastuzumab Deruxtecan in HER2-Positive Breast Cancer: A Systematic Review and Meta-Analysis of the DESTINY-Breast Trials (ESMO 2026) - No abstract available

Retrospective data • Review • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Redefining HER2-Low Breast Cancer: Clinical Impact of Trastuzumab Deruxtecan and Antibody–Drug Conjugates (ESMO 2026) - No abstract available

ADC • Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

Interstitial pneumonitis related to Trastuzumab Deruxtecan in patients with metastatic breast cancer: risk factors, incidence and management (ESMO 2026) - No abstract available

Clinical • Metastases • Breast Cancer • Oncology • Solid Tumor

Sequencing sacituzumab govitecan and trastuzumab deruxtecan in metastatic triple-negative breast cancer (mTNBC): real-world overall survival from an expanded Italian cohort. (ESMO 2026) - No abstract available

Clinical • Metastases • Real-world • Real-world evidence • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Real-World Comparative Analysis of Trastuzumab Deruxtecan (T-DXd) and Sacituzumab Govitecan (SG) in Triple-Negative Metastatic Breast Cancer: A Multicenter Clinical Outcome Study (ESMO 2026) - No abstract available

Clinical • Clinical data • Metastases • Real-world • Real-world evidence • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer

Beyond HER2 IHC: ERBB2 RNA-ISH Stratifies Benefit from T-DXd Combinations (ESMO 2026) - No abstract available

Oncology • HER-2

Pharmacogenetic variants associated with interstitial lung disease in patients with advanced breast cancer treated with Trastuzumab-deruxtecan: results from the PROCURE Project (ESMO 2026) - No abstract available

Biomarker • Clinical • Metastases • Breast Cancer • Oncology • Solid Tumor